Issue Date: November 20, 2017
CRISPR antibiotics company raises cash
Locus Biosciences has raised $19 million in a series A funding round to develop antibiotics with CRISPR. While most gene-editing companies are working with CRISPR/Cas9 to make fine-tuned cuts in human DNA, Research Triangle Park, N.C.-based Locus is using a version of CRISPR, called CRISPR/Cas3, that acts more like a chainsaw, tearing up precisely targeted bacterial DNA. Investors include Tencent Holdings, Abstract Ventures, and the North Carolina Biotechnology Center.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society